MA32542B1 - Compositions pharmaceutiques a base d'antagonistes du recepteur b2 de la kinine et de corticosteroides et leur utilisation - Google Patents

Compositions pharmaceutiques a base d'antagonistes du recepteur b2 de la kinine et de corticosteroides et leur utilisation

Info

Publication number
MA32542B1
MA32542B1 MA33588A MA33588A MA32542B1 MA 32542 B1 MA32542 B1 MA 32542B1 MA 33588 A MA33588 A MA 33588A MA 33588 A MA33588 A MA 33588A MA 32542 B1 MA32542 B1 MA 32542B1
Authority
MA
Morocco
Prior art keywords
kinin
pharmaceutical compositions
corticosteroids
receptor antagonists
compositions based
Prior art date
Application number
MA33588A
Other languages
Arabic (ar)
English (en)
Inventor
Sandro Giuliani
Carlo Alberto Maggi
Original Assignee
Luso Farmaco Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luso Farmaco Inst filed Critical Luso Farmaco Inst
Publication of MA32542B1 publication Critical patent/MA32542B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques renfermant, en tant que principes actifs, un mélange d'un corticostéroïde et d'un antagoniste du récepteur b2 de la kinine. Lesdites compositions se sont révélées particulièrement efficaces, spécialement dans le traitement de troubles inflammatoires tels que l'asthme, de troubles ophtalmiques ou dermatologiques et, par-dessus tout, par rapport aux articulations, de l'arthrite.
MA33588A 2008-07-11 2011-02-08 Compositions pharmaceutiques a base d'antagonistes du recepteur b2 de la kinine et de corticosteroides et leur utilisation MA32542B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2008A001264A IT1391236B1 (it) 2008-07-11 2008-07-11 Composizioni farmaceutiche a base di antagonisti del recettore b2 delle chinine e corticosteroidi e loro uso
PCT/EP2009/004847 WO2010003601A1 (fr) 2008-07-11 2009-07-03 Compositions pharmaceutiques à base d’antagonistes du récepteur b2 de la kinine et de corticostéroïdes et leur utilisation

Publications (1)

Publication Number Publication Date
MA32542B1 true MA32542B1 (fr) 2011-08-01

Family

ID=40466843

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33588A MA32542B1 (fr) 2008-07-11 2011-02-08 Compositions pharmaceutiques a base d'antagonistes du recepteur b2 de la kinine et de corticosteroides et leur utilisation

Country Status (35)

Country Link
US (1) US8476276B2 (fr)
EP (1) EP2303268B1 (fr)
JP (1) JP5791501B2 (fr)
KR (1) KR101656324B1 (fr)
CN (1) CN102088975B (fr)
AP (1) AP2803A (fr)
AR (1) AR072734A1 (fr)
AU (1) AU2009267416B2 (fr)
BR (1) BRPI0915866A2 (fr)
CA (1) CA2730420A1 (fr)
CO (1) CO6341556A2 (fr)
CR (1) CR20110021A (fr)
CY (1) CY1112900T1 (fr)
DK (1) DK2303268T3 (fr)
EA (1) EA019903B1 (fr)
EC (1) ECSP11010752A (fr)
ES (1) ES2389872T3 (fr)
GE (1) GEP20135792B (fr)
HN (1) HN2011000089A (fr)
HR (1) HRP20120678T1 (fr)
IL (1) IL210554A0 (fr)
IT (1) IT1391236B1 (fr)
MA (1) MA32542B1 (fr)
MX (1) MX2011000350A (fr)
MY (1) MY150477A (fr)
NI (1) NI201100014A (fr)
NZ (1) NZ590427A (fr)
PL (1) PL2303268T3 (fr)
PT (1) PT2303268E (fr)
RS (1) RS52418B (fr)
SI (1) SI2303268T1 (fr)
TW (1) TWI499419B (fr)
UA (1) UA100060C2 (fr)
WO (1) WO2010003601A1 (fr)
ZA (1) ZA201100287B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
KR20150127718A (ko) * 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. Ｂ2-브라디키닌 수용체 매개 혈관부종의 치료 방법
CN104072585A (zh) * 2014-07-21 2014-10-01 成都圣诺生物科技股份有限公司 一种合成艾替班特的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2451602A1 (fr) * 2001-06-26 2003-01-03 Metaphore Pharmaceuticals, Inc. Therapie de combinaison d'un mimetique d'enzyme superoxyde-dismutase (sodm) et d'un corticosteroide destinee a la prevention et/ou au traitement de maladie inflammatoire
ITMI20021247A1 (it) * 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
DE10304994A1 (de) * 2003-02-07 2004-09-02 Aventis Pharma Deutschland Gmbh Die Verwendung von Antagonisten des Bradykinin-B2 Rezeptors zur Behandlung von Osteoarthrose
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
EP1741444A1 (fr) * 2005-07-05 2007-01-10 Jerini AG Antagonistes de kinine pour traiter le dysfonctionnement de la vessie
EP1894559A1 (fr) * 2006-09-01 2008-03-05 PARI Pharma GmbH Stabilisation de stéroides destinées à être inhalées

Also Published As

Publication number Publication date
IL210554A0 (en) 2011-03-31
KR101656324B1 (ko) 2016-09-09
HK1158547A1 (en) 2012-07-20
JP2011527296A (ja) 2011-10-27
JP5791501B2 (ja) 2015-10-07
DK2303268T3 (da) 2012-07-23
PT2303268E (pt) 2012-09-24
TWI499419B (zh) 2015-09-11
CN102088975B (zh) 2013-08-21
US20110112011A1 (en) 2011-05-12
BRPI0915866A2 (pt) 2015-11-03
WO2010003601A1 (fr) 2010-01-14
CY1112900T1 (el) 2016-04-13
SI2303268T1 (sl) 2012-10-30
US8476276B2 (en) 2013-07-02
AR072734A1 (es) 2010-09-15
ITMI20081264A1 (it) 2010-01-12
AU2009267416B2 (en) 2013-09-12
ZA201100287B (en) 2012-03-28
CN102088975A (zh) 2011-06-08
WO2010003601A8 (fr) 2010-03-18
HN2011000089A (es) 2013-01-28
MY150477A (en) 2014-01-30
RS52418B (sr) 2013-02-28
AP2803A (en) 2013-11-30
ECSP11010752A (es) 2011-04-29
PL2303268T3 (pl) 2012-11-30
UA100060C2 (uk) 2012-11-12
EA201100013A1 (ru) 2011-08-30
EP2303268A1 (fr) 2011-04-06
CO6341556A2 (es) 2011-11-21
EA019903B1 (ru) 2014-07-30
NI201100014A (es) 2011-09-13
AU2009267416A1 (en) 2010-01-14
KR20110044970A (ko) 2011-05-03
AP2011005572A0 (en) 2011-02-28
NZ590427A (en) 2012-09-28
EP2303268B1 (fr) 2012-06-20
TW201006471A (en) 2010-02-16
IT1391236B1 (it) 2011-12-01
CA2730420A1 (fr) 2010-01-14
CR20110021A (es) 2011-07-11
HRP20120678T1 (hr) 2012-09-30
ES2389872T3 (es) 2012-11-02
MX2011000350A (es) 2011-02-22
GEP20135792B (en) 2013-03-25

Similar Documents

Publication Publication Date Title
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
MA33538B1 (fr) Nouveaux antagonistes pyrimidine et triazine de l'hepcidine
MX340538B (es) Compuestos amido y sus usos como farmaceuticos.
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
NO20072322L (no) Laktamforbindelser og anvendelse derav som farmasoytiske midler
WO2007112288A3 (fr) Composition cardiovasculaire et utilisation de ladite composition pour le traitement de la maladie d'alzheimer
TW200626156A (en) Amido compounds and their use as pharmaceuticals
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA33295B1 (fr) Nouvelle formulation de diclofénac
WO2006002361A3 (fr) 2-methylpropanamides et leur utilisation comme produits pharmaceutiques
WO2007038138A3 (fr) Utilisation pharmaceutique de composes amido
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
WO2006012227A3 (fr) Composes amido et utilisations de ces derniers en tant que produits pharmaceutiques
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
CA2643130A1 (fr) Composes et procedes destines au traitement de troubles associes a l'activation des cellules metachromatiques
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA35937B1 (fr) Composés substitués de chromane en tant que modulateurs des récepteurs de détection du calcium
MA34135B1 (fr) Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique
BRPI0414558A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
UY29995A1 (es) Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia
BRPI0617673C1 (pt) composições de inibidores de fosfodiesterase do tipo iv